163 related articles for article (PubMed ID: 19634915)
21. Transmembrane diffusion of gemcitabine by a nanoparticulate squalenoyl prodrug: an original drug delivery pathway.
Bildstein L; Dubernet C; Marsaud V; Chacun H; Nicolas V; Gueutin C; Sarasin A; Bénech H; Lepêtre-Mouelhi S; Desmaële D; Couvreur P
J Control Release; 2010 Oct; 147(2):163-70. PubMed ID: 20691740
[TBL] [Abstract][Full Text] [Related]
22. Circulating Lipoproteins: A Trojan Horse Guiding Squalenoylated Drugs to LDL-Accumulating Cancer Cells.
Sobot D; Mura S; Rouquette M; Vukosavljevic B; Cayre F; Buchy E; Pieters G; Garcia-Argote S; Windbergs M; Desmaële D; Couvreur P
Mol Ther; 2017 Jul; 25(7):1596-1605. PubMed ID: 28606375
[TBL] [Abstract][Full Text] [Related]
23. Squalenoyl-gemcitabine/edelfosine nanoassemblies: Anticancer activity in pediatric cancer cells and pharmacokinetic profile in mice.
Rodríguez-Nogales C; Mura S; Couvreur P; Blanco-Prieto MJ
Int J Pharm; 2020 May; 582():119345. PubMed ID: 32311470
[TBL] [Abstract][Full Text] [Related]
24. Novel nanoassemblies composed of squalenoyl-paclitaxel derivatives: synthesis, characterization, and biological evaluation.
Dosio F; Reddy LH; Ferrero A; Stella B; Cattel L; Couvreur P
Bioconjug Chem; 2010 Jul; 21(7):1349-61. PubMed ID: 20597546
[TBL] [Abstract][Full Text] [Related]
25. Self-assembled squalenoyl-cytarabine nanostructures as a potent nanomedicine for treatment of leukemic diseases.
Cosco D; Rocco F; Ceruti M; Vono M; Fresta M; Paolino D
Int J Nanomedicine; 2012; 7():2535-46. PubMed ID: 22679366
[TBL] [Abstract][Full Text] [Related]
26. Chlorambucil gemcitabine conjugate nanomedicine for cancer therapy.
Fan M; Liang X; Li Z; Wang H; Yang D; Shi B
Eur J Pharm Sci; 2015 Nov; 79():20-6. PubMed ID: 26342774
[TBL] [Abstract][Full Text] [Related]
27. Superior preclinical efficacy of gemcitabine developed as chitosan nanoparticulate system.
Arias JL; Reddy LH; Couvreur P
Biomacromolecules; 2011 Jan; 12(1):97-104. PubMed ID: 21117615
[TBL] [Abstract][Full Text] [Related]
28. Characterization of a gemcitabine-resistant murine leukemic cell line: reversion of in vitro resistance by a mononucleotide prodrug.
Jordheim LP; Cros E; Gouy MH; Galmarini CM; Peyrottes S; Mackey J; Perigaud C; Dumontet C
Clin Cancer Res; 2004 Aug; 10(16):5614-21. PubMed ID: 15328204
[TBL] [Abstract][Full Text] [Related]
29. Efficient overcoming of drug resistance to anticancer nucleoside analogs by nanodelivery of active phosphorylated drugs.
Galmarini CM; Warren G; Senanayake MT; Vinogradov SV
Int J Pharm; 2010 Aug; 395(1-2):281-9. PubMed ID: 20580798
[TBL] [Abstract][Full Text] [Related]
30. ["Squalenoylation": a new approach to the design of anticancer and antiviral nanomedicines].
Couvreur P
Bull Acad Natl Med; 2009 Mar; 193(3):663-73; discussion 673-4. PubMed ID: 19883017
[TBL] [Abstract][Full Text] [Related]
31. Biomimetic nanoassemblies of 1-O-octodecyl-2-conjugated linoleoyl-sn-glycero-3-phosphatidyl gemcitabine with phospholipase A
Zuo J; Tong L; Du L; Yang M; Jin Y
Colloids Surf B Biointerfaces; 2017 Apr; 152():467-474. PubMed ID: 28187380
[TBL] [Abstract][Full Text] [Related]
32. Caspase activation is required for gemcitabine activity in multiple myeloma cell lines.
Nabhan C; Gajria D; Krett NL; Gandhi V; Ghias K; Rosen ST
Mol Cancer Ther; 2002 Nov; 1(13):1221-7. PubMed ID: 12479703
[TBL] [Abstract][Full Text] [Related]
33. Self-assembled drug delivery systems. Part 6: in vitro/in vivo studies of anticancer N-octadecanoyl gemcitabine nanoassemblies.
Jin Y; Lian Y; Du L; Wang S; Su C; Gao C
Int J Pharm; 2012 Jul; 430(1-2):276-81. PubMed ID: 22486963
[TBL] [Abstract][Full Text] [Related]
34. Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit.
Jung CP; Motwani MV; Schwartz GK
Clin Cancer Res; 2001 Aug; 7(8):2527-36. PubMed ID: 11489836
[TBL] [Abstract][Full Text] [Related]
35. Application of activated nucleoside analogs for the treatment of drug-resistant tumors by oral delivery of nanogel-drug conjugates.
Senanayake TH; Warren G; Wei X; Vinogradov SV
J Control Release; 2013 Apr; 167(2):200-9. PubMed ID: 23385032
[TBL] [Abstract][Full Text] [Related]
36. Gemcitabine-induced apoptosis in a drug-resistant mouse leukemia L1210 cell line that does not express p53.
Cory AH; Cory JG
Adv Enzyme Regul; 2004; 44():11-25. PubMed ID: 15581479
[No Abstract] [Full Text] [Related]
37. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.
Denlinger CE; Rundall BK; Keller MD; Jones DR
Ann Thorac Surg; 2004 Oct; 78(4):1207-14; discussion 1207-14. PubMed ID: 15464472
[TBL] [Abstract][Full Text] [Related]
38. Polyisoprenoyl gemcitabine conjugates self assemble as nanoparticles, useful for cancer therapy.
Maksimenko A; Mougin J; Mura S; Sliwinski E; Lepeltier E; Bourgaux C; Lepêtre S; Zouhiri F; Desmaële D; Couvreur P
Cancer Lett; 2013 Jul; 334(2):346-53. PubMed ID: 22935679
[TBL] [Abstract][Full Text] [Related]
39. Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells.
Serova M; Galmarini CM; Ghoul A; Benhadji K; Green SR; Chiao J; Faivre S; Cvitkovic E; Le Tourneau C; Calvo F; Raymond E
Br J Cancer; 2007 Sep; 97(5):628-36. PubMed ID: 17637678
[TBL] [Abstract][Full Text] [Related]
40. Squalenoylation: a generic platform for nanoparticular drug delivery.
Desmaële D; Gref R; Couvreur P
J Control Release; 2012 Jul; 161(2):609-18. PubMed ID: 21840355
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
